Dapivirine vs Emtricitabine (Emtriva)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Dapivirine · Dapivirine Vaginal Ring
Marketed by Population Council and partners
NCT01617096 · Phase 3 · completed
This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.
Reported efficacy
Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)
Result source: NCT01617096
Emtricitabine (Emtriva)
Marketed by Gilead Sciences and partners
NCT00112047 · Phase 3 · completed
The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.
Next expected readout: June 2029 · NCT07792096 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)
Result source: NCT00112047
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapivirine | Emtricitabine (Emtriva) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06250504 | —Not posted · NCT00002416 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06250504 | —Not posted · NCT00002416 |
| CD4 count, change (week 48) | —Trial running · NCT06250504 | —Not posted · NCT00002416 |
HIV-1 RNA below 50 copies/mL (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
HIV-1 RNA 50 copies/mL or more (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
CD4 count, change (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dapivirine: 4 of 4 rows · Emtricitabine (Emtriva): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapivirine |
|---|---|
| Dropout rate | 11.3%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results9.9%25 mg NCT02862171 · Phase 3 3.6%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence 5.5% NCT02028338 · Phase 2 · registry result, not featured evidence 2.8% NCT02010593 · Phase 2 · registry result, not featured evidence 20.9%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 23.3%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 10.5% NCT03239483 · Phase 1 · registry result, not featured evidence 31% NCT01539226 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results—25 mg NCT02862171 · Phase 3 —25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence — NCT02028338 · Phase 2 · registry result, not featured evidence — NCT02010593 · Phase 2 · registry result, not featured evidence 4.7%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence — NCT03239483 · Phase 1 · registry result, not featured evidence 0% NCT01539226 · Phase na · registry result, not featured evidence |
| Serious AEs | 8.8%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results2.1%25 mg NCT02862171 · Phase 3 1.4%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence 0% NCT03593655 · Phase 2 · registry result, not featured evidence 2.7% NCT02028338 · Phase 2 · registry result, not featured evidence 1.4% NCT02010593 · Phase 2 · registry result, not featured evidence 2.3%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0% NCT03239483 · Phase 1 · registry result, not featured evidence 3.1% NCT01539226 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg DVR inserted once every 4 weeksa metrorrhagia 55.1% (placebo 55.6%) genitourinary chlamydia infection 20.5% (placebo 20.8%) menorrhagia 19.7% (placebo 18.4%) NCT01617096 · Phase 3 · monotherapy show 9 more results25 mg vaginal matrix ring genitourinary chlamydia infection 8.4% vaginal discharge 8% vulvovaginitis trichomonal 5.9% NCT02858037 · Phase 3 · registry result, not featured evidence any event in soc 58.5% any event in soc 32.4% creatinine renal clearance decreased 30.3% NCT03593655 · Phase 2 · registry result, not featured evidence metrorrhagia 20.5% (placebo 26.1%) vaginal discharge 15.1% (placebo 34.8%) bacterial vaginosis 12.3% (placebo 8.7%) NCT02028338 · Phase 2 · registry result, not featured evidence vaginal discharge 11.1% (placebo 12.5%) upper respiratory tract infection 8.3% (placebo 12.5%) vaginal odour 6.9% (placebo 0%) NCT02010593 · Phase 2 · registry result, not featured evidence vaginitis bacterial 16.3% (placebo 11.9%) vaginal candidiasis 9.3% (placebo 0%) abdominal pain lower 4.7% (placebo 0%) NCT00799058 · Phase 1/2 · registry result, not featured evidence vaginitis bacterial 34.9% (placebo 11.9%) vulvovaginal pruritus 9.3% (placebo 4.8%) headache 7% (placebo 7.1%) NCT00799058 · Phase 1/2 · registry result, not featured evidence diarrhoea 11.1% (placebo 22.2%) insomnia 11.1% (placebo 0%) anal pruritus 5.6% (placebo 0%) NCT03239483 · Phase 1 · registry result, not featured evidence gynaecological chlamydia infection 32.7% (placebo 32.7%) metrorrhagia 27% (placebo 29.6%) genital infection female 23% (placebo 19.3%) NCT01539226 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapivirine
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Emtricitabine (Emtriva)'s landscape